ZIOPHARM (ZIOP) Taps Former Sanofi (SNY) Exec Amello as CFO
Tweet
Share
E-mailGet Alerts ZIOP Hot Sheet
Join SI Premium – FREE
ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) has appointed Jason A. Amello as Executive Vice President and Chief Financial Officer of the Company. In this position, Mr. Amello will lead ZIOPHARM's financial and capital markets activities, as well as advise on business development and transactional activities, and report to Jonathan Lewis, M.D., Ph.D., Chief Executive Officer of ZIOPHARM.
Mr. Amello has over 20 years of leadership experience guiding strategic business growth and operational performance through roles covering finance, accounting, corporate and capital markets strategies and mergers and acquisitions. For 11 years, Mr. Amello served in various roles of increasing responsibility at Genzyme Corporation, a Sanofi company (NYSE: SNY), most recently as Senior Vice President, Corporate Controller and Chief Accounting Officer. While at Genzyme, Mr. Amello served as one of the key executives in connection with the company's extensive mergers and acquisition and corporate partnering activities, which contributed to Genzyme's 5-fold growth over 10 years. Prior to Genzyme, Mr. Amello spent 10 years in the business advisory and assurance practice of Deloitte & Touche, serving in various roles of increasing responsibility through Senior Manager. Mr. Amello holds a B.S. degree from Boston College and is a Certified Public Accountant in the Commonwealth of Massachusetts.
Mr. Amello has over 20 years of leadership experience guiding strategic business growth and operational performance through roles covering finance, accounting, corporate and capital markets strategies and mergers and acquisitions. For 11 years, Mr. Amello served in various roles of increasing responsibility at Genzyme Corporation, a Sanofi company (NYSE: SNY), most recently as Senior Vice President, Corporate Controller and Chief Accounting Officer. While at Genzyme, Mr. Amello served as one of the key executives in connection with the company's extensive mergers and acquisition and corporate partnering activities, which contributed to Genzyme's 5-fold growth over 10 years. Prior to Genzyme, Mr. Amello spent 10 years in the business advisory and assurance practice of Deloitte & Touche, serving in various roles of increasing responsibility through Senior Manager. Mr. Amello holds a B.S. degree from Boston College and is a Certified Public Accountant in the Commonwealth of Massachusetts.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boeing names Ryan Shedd as new SVP and controller
- Qnity Electronics names Ken Rizvi as CFO, effective October 1
- Balfour Beatty names Sarah Brand VP of Tampa buildings ops
Create E-mail Alert Related Categories
Management ChangesRelated Entities
Genzyme/Sanofi-AventisSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
